Sumitomo Pharma Co.

4506.TSE

11.65 USD

-0.02

-0.17%

Overview

Last close

11.65 usd

Market cap

5.23B usd

52 week high

20.84 usd

52 week low

3.56 usd

Target price

14.11 usd

Valuation

P/E

7.6808

Forward P/E

20.202

Price/Sales

1.7404

Price/Book Value

1.767

Enterprise Value

5.06B usd

EV/Revenue

1.762

EV/EBITDA

7.2258

Key financials

Revenue TTM

3.01B usd

Gross Profit TTM

1.65B usd

EBITDA TTM

432.68M usd

Earnings per Share

1.52 usd

Dividend

N/A usd

Total assets

5.20B usd

Net debt

516.83M usd

About

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.